{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-116847","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2024-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.053907+00:00","generated_at":"2026-05-30T10:22:45.601569+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"EyePoint doses first patient in Phase 3 LUGANO trial of DURAVYU for wet AMD; LUCIA trial by end 2024, topline 2026","bullets":["First patient dosed in global Phase 3 LUGANO trial of DURAVYU (vorolanib) for wet AMD; non-inferiority design vs aflibercept.","Second Phase 3 LUCIA trial first dosing expected by end of 2024; topline data anticipated in 2026.","Trials enroll ~400 patients each; DURAVYU dosed every 6 months vs on-label aflibercept every 2 months, after 3 loading doses.","Over 190 patients previously treated in DAVIO/DAVIO 2; favorable safety; treatment-naïve and treatment-experienced included.","Re-dosing evaluated in both trials; primary endpoint: average change in BCVA at weeks 52 and 56 vs baseline."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-116847","json":"https://secwatch.observer/filing/0000950170-24-116847.json","markdown":"https://secwatch.observer/filing/0000950170-24-116847.md","text":"https://secwatch.observer/filing/0000950170-24-116847.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024116847/0000950170-24-116847-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024116847/eypt-20241022.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:22:45.601569+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}